Harley-Davidson Delivers Fourth Quarter and Full Year Financial Results and 2025 Outlook

Harley-Davidson, Inc. (“Harley-Davidson,” “HDI,” or the “Company”)(NYSE: HOG) today reported fourth quarter and full year 2024 results and provided 2025 Outlook. “In 2024, we saw our performance being significantly impacted by the continued cyclical headwinds for discretionary products, including the high-interest rate environment affecting consumer confidence,” said Jochen Zeitz, Chairman, President and CEO, Harley-Davidson. “The […]

Spire reports FY25 first quarter results

Spire Inc. (NYSE: SR) today reported results for its fiscal 2025 first quarter ended December 31. Highlights include: https://mma.prnewswire.com/media/1818129/Spire_Logo.jpg — First quarter net income of $81.3 million ($1.34 per diluted share) compared to $85.1 million ($1.52 per share) a year ago — First quarter adjusted earnings* of $81.1 million ($1.34 per share) compared to $82.7

Tim Hortons raises record-breaking $1.3 million through Special Olympics Donuts, with 100 per cent of proceeds donated to Special Olympics Canada

Tim Hortons is proud to share that a record-breaking $1.3 million was raised through the sale of Special Olympics Donuts, with 100 per cent of proceeds being donated to Special Olympics Canada. The funds raised will help Canadian athletes with intellectual and developmental disabilities access more opportunities to reach their full potential in sport and

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

(NYSE MKT:CANF),(TASE:CFBI),(TASE:CANF.TA), Ramat Gan, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it will present at the BIO CEO & Investor Conference, taking place February 10-11, 2025, in New

Ethical Web AI appoints Tom Symonds as the new Chief Executive Officer

(Other OTC:BBLR),(OTC US:BBLR), NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) — Ethical Web AI (d/b/a Bubblr Inc.) (OTC: BBLR), a leader in ethical technology innovation, proudly announces the appointment of Tom Symonds as Chief Executive Officer. Tom has been at the forefront of innovative technology for 25 years. He is a recognized pioneer in the

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

(TSX:MDNA),(OTC US:MDNAF),(Other OTC:MDNAF), TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer, and inflammatory and autoimmune diseases, today announced that its management team will participate in two upcoming investor conferences in

BioXcel Therapeutics Provides Clinical and Business Update

(NASDAQ:BTAI), Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia Developed plans for TRANQUILITY In-Care Phase 3 trial of BXCL501 for agitation associated with Alzheimer's dementia Enhanced operational and financial flexibility through existing credit amendment Strengthened strategic leadership with recent Board appointments

Ascot Resources Provides Further Update on CEO Review

(TSX:AOT),(OTC US:AOTVF),(Other OTC:AOTVF), VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) — Ascot Resources Ltd. (TSX: AOT; OTCQX: AOTVF) (“Ascot” or the “Company“) is providing an update on the progress of the Premier Gold Project following an initial review conducted by President and Chief Executive Officer Jim Currie and his management team. Due to the

Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity Investment

(CNSX:AGN.CN),(OTC US:AGNPF),(Other OTC:AGNPF),(CNSX:AGN),(Boerse Frankfurt – Freiverkehr:AGW0.F), VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary, Algernon NeuroScience (AGN Neuro), has appointed Validcare as the contract

ValOre Affiliate Hatchet Uranium Corp. Closes $1,500,000 Financing Related to Saskatchewan Uranium Properties Acquisitions

(TSX-V:VO),(OTC US:KVLQF),(Other OTC:KVLQF),(Frankfurt:KEQ0), VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) — ValOre Metals Corp. (“ValOre”; TSXâ€V: VO; OTCQB: KVLQF; Frankfurt: KEQ0) today provided an update on developments concerning Hatchet Uranium Corp. (“Hatchet”), in which ValOre currently holds an approximate 56.8% ownership interest. Hatchet entered into agreements (the “Transactions”) with Skyharbour Resources Ltd. (“Skyharbour”), (CLICK

Scroll to Top